A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers (S5.005)
Qureshi I, Coric V, Gentile K, Larouche R, Tanguay M, Berman R. A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers (S5.005). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.s5.005.Peer-Reviewed Original Research